Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study
dc.contributor.author | Bingham, Clifton O. | en_US |
dc.contributor.author | Buckland-Wright, J. Chris | en_US |
dc.contributor.author | Garnero, Patrick | en_US |
dc.contributor.author | Cohen, Stanley B. | en_US |
dc.contributor.author | Dougados, Maxime | en_US |
dc.contributor.author | Adami, Silvano | en_US |
dc.contributor.author | Clauw, Daniel J. | en_US |
dc.contributor.author | Spector, Timothy D. | en_US |
dc.contributor.author | Pelletier, Jean-Pierre | en_US |
dc.contributor.author | Raynauld, Jean-Pierre | en_US |
dc.contributor.author | Strand, Vibeke | en_US |
dc.contributor.author | Simon, Lee S. | en_US |
dc.contributor.author | Meyer, Joan M. | en_US |
dc.contributor.author | Cline, Gary A. | en_US |
dc.contributor.author | Beary, John F. | en_US |
dc.date.accessioned | 2007-09-20T17:49:08Z | |
dc.date.available | 2008-01-03T16:20:57Z | en_US |
dc.date.issued | 2006-11 | en_US |
dc.identifier.citation | Bingham, Clifton O.; Buckland-Wright, J. Chris; Garnero, Patrick; Cohen, Stanley B.; Dougados, Maxime; Adami, Silvano; Clauw, Daniel J.; Spector, Timothy D.; Pelletier, Jean-Pierre; Raynauld, Jean-Pierre; Strand, Vibeke; Simon, Lee S.; Meyer, Joan M.; Cline, Gary A.; Beary, John F. (2006). "Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study." Arthritis & Rheumatism 54(11): 3494-3507. <http://hdl.handle.net/2027.42/55858> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55858 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17075851&dopt=citation | en_US |
dc.description.abstract | Objective Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal models and have decreased pain in states of high bone turnover. The Knee OA Structural Arthritis (KOSTAR) study, which is the largest study to date investigating a potential structure-modifying OA drug, tested the efficacy of risedronate in providing symptom relief and slowing disease progression in patients with knee OA. Methods The study group comprised 2,483 patients with medial compartment knee OA and 2–4 mm of joint space width (JSW), as determined using fluoroscopically positioned, semiflexed-view radiography. Patients were enrolled in 2 parallel 2-year studies in North America and the European Union. These studies evaluated the efficacy of risedronate at dosages of 5 mg/day, 15 mg/day, 35 mg/week (in Europe), and 50 mg/week (in North America) compared with placebo in reducing signs and symptoms, as measured by the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and patient global assessment (PGA) scores, and in slowing radiographic progression. Results A reduction of ∼20% in signs and symptoms, as measured by WOMAC subscales and PGA scores, was observed in all groups, with no treatment effect of risedronate demonstrated. Risedronate did not significantly reduce radiographic progression as measured by decreased JSW or using a dichotomous definition of progression (joint space loss of ≥0.6 mm). Thirteen percent of patients receiving placebo demonstrated significant disease progression over 2 years. A dose-dependent reduction in the level of C-terminal crosslinking telopeptide of type II collagen, a cartilage degradation marker associated with progressive OA, was seen in patients who received risedronate. No increase in the number of adverse events was demonstrated for risedronate compared with placebo. Conclusion Although risedronate (compared with placebo) did not improve signs or symptoms of OA, nor did it alter progression of OA, a reduction in the level of a marker of cartilage degradation was observed. A sustained clinically relevant improvement in signs and symptoms was observed in all treatment and placebo groups. | en_US |
dc.format.extent | 235781 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationother | Johns Hopkins University, Baltimore, Maryland ; Dr. Bingham has received consulting fees (less than $10,000) from Procter & Gamble. Dr. Cohen has received consulting fees and/or honoraria (less than $10,000) from Procter & Gamble. Dr. Dougados has received consulting fees and/or honoraria (less than $10,000) from Procter & Gamble. Dr. Adami has received consulting fees and/or honoraria (less than $10,000) from Procter & Gamble. Dr. Spector has received consulting fees and/or honoraria (more than $10,000) from Procter & Gamble. Dr. Strand has served as a consultant to and/or has received honoraria (less than $10,000 each) from Abbott Immunology, Amgen, Biogen Idec, Can-Fite BioPharma Ltd., Celera, Centocor, Chelsea Therapeutics, Coley Pharmaceutical Group, Cypress Pharmaceutical, FibroGen, Genelabs Technologies, Genentech, Human Genome Sciences, Immunomedics, Incyte Pharmaceuticals, Millennium Pharmaceuticals, Novartis, Omeros, Pfizer, Procter & Gamble, Rigel Pharmaceuticals, Roche, Sanofi Aventis, Schering-Plough, Scios, Serono, Sanwa Kagaku Kenkyusho Ltd., Sumitomo, UCB Pharma, XDx, and Xencor. Additionally, Dr. Strand serves on advisory boards for Abbott Immunology, Alder Biopharmaceuticals, Amgen, BioSeek, CanFite BioPharma, Centocor, Chelsea Therapeutics, Jazz Pharmaceuticals, Novartis, Pfizer, Robert Wood Johnson Pharmaceutical Research Institute, Roche, Sanofi-Aventis, Savient Pharmaceuticals, UCB Pharma, and Wyeth, and serves on speaking bureaus for Abbott Immunology, Amgen, Centocor, Novartis, Pfizer, and Santofi-Adventis. ; Divisions of Rheumatology and Allergy and Clinical Immunology, Johns Hopkins University, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Room 404, Baltimore, MD 21224 | en_US |
dc.contributor.affiliationother | King's College, London, UK | en_US |
dc.contributor.affiliationother | INSERM Research Unit 664, and Synarc, Lyon, France | en_US |
dc.contributor.affiliationother | St. Paul Medical Center, Dallas, Texas | en_US |
dc.contributor.affiliationother | HÔpital Cochin, Paris, France | en_US |
dc.contributor.affiliationother | University of Verona, Verona, Italy | en_US |
dc.contributor.affiliationother | St. Thomas Hospital, London, UK | en_US |
dc.contributor.affiliationother | Centre Hospitalier de l'UniversitÉ de MontrÉal, HÔpital Notre-Dame, MontrÉal, QuÉbec, Canada | en_US |
dc.contributor.affiliationother | Centre Hospitalier de l'UniversitÉ de MontrÉal, HÔpital Notre-Dame, MontrÉal, QuÉbec, Canada | en_US |
dc.contributor.affiliationother | Stanford University School of Medicine, Palo Alto, California | en_US |
dc.contributor.affiliationother | Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachussetts | en_US |
dc.contributor.affiliationother | Procter & Gamble Pharmaceuticals, Mason, Ohio | en_US |
dc.contributor.affiliationother | Procter & Gamble Pharmaceuticals, Mason, Ohio | en_US |
dc.contributor.affiliationother | Procter & Gamble Pharmaceuticals, Mason, Ohio | en_US |
dc.identifier.pmid | 17075851 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55858/1/22160_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/art.22160 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.